Phase 4 N=21 Prophylaxis Regimen for Hemophilia A Patients
Hemophilia A · Prophylaxis of Bleeding
Primary: Overall Number of Participants With Favorable Outcome on the Score-assigned Prophylaxis Regimen — 12 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=99 Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China
Relapsing Multiple Sclerosis
Primary: Adjusted Annualized Relapse Rate (ARR) Based on Confirmed Relapses — 0.05 relapses per participant-year
Phase 4 N=21 Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Esophageal Eosinophilia (Number of Eosinophils in the Esophagus) — 5.3 eosinophils/high power field
Phase 4 N=92 Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate
Atrial Fibrillation With Rapid Ventricular Response · Hypotension Drug-Induced
Primary: Mean Difference in Systolic Blood Pressure — -11.7500; -19.5385 mmHg
Phase 4 N=86 Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization
Chronic Pain
Primary: Pain Intensity — 11; 29 Participants
Phase 4 N=132 Comparison Between Dexamethasone and Ibuprofen on Pain Prevention and Control Following Surgical Implant Placement
Pain Measurement
Primary: The Visual Analog Scale (VAS) Was Used to Measures Levels of Pain. — 2; 2; 5.0 score on a scale
Phase 4 N=55 Effect of Knee Pain on Walking Biomechanics
Osteoarthritis, Knee
Primary: Change in Medial Knee Contact Forces During Walking — -0.04 bodyweights
Phase 4 N=414 Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
Chemotherapy-induced Nausea and Vomiting
Primary: The Probability of Complete Responses Over Three Cycles of Chemotherapy After the Start of the MEC Administration — 0.810; 0.718 Probability of complete response — p=<0.05
Phase 4 N=36 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Bariatric Surgery Candidate · Bone Loss
Primary: Percentage Change in Total Hip Bone Mineral Density — 0.60; -6.44 percentage of change
Phase 4 N=52 Tobacco Treatment Comparison for Cancer Care
Smoking Cessation · Cancer
Primary: Biochemically Verified 7-day Point-prevalence Abstinence 26 Weeks After a Target Quit Date. — 2; 7 Participants
Phase 4 N=100 Suvorexant and Sleep/Delirium in ICU Patients
Insomnia · Sleep Fragmentation · Sleep Initiation and Maintenance Disorders
Primary: Nighttime Wakefulness After Persistent Sleep Onset (WASO) — 200.7; 184.2 minutes
Phase 4 N=152 Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
Respiratory Syncytial Virus (RSV)
Primary: Geometric Mean Fold Rise Against RSV Fa Protein — 12.5; 9.9 fold change — p=0.14
Phase 4 N=360 EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Chronic Rhinosinusitis With Nasal Polyps · Asthma
Primary: Change From Baseline to Week 24 in Nasal Polyp Score — -2.65; -1.05 score on a scale — p=<0.001
Phase 4 N=70 Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery
Cardiovascular Surgery · Pain, Postoperative · Block
Primary: Total Postoperative Opioid Measured in Milligram Morphine Equivalent (MME) at 72 Hours — 29.4; 25.8 Milligram Morphine Equivalent (MME)
Phase 4 N=48 The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Change in Exercise Time (Seconds) During Cycle Ergometer Exercise. — 382.50; 328 seconds